NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT ® technology, today announced the appointments of Jack A. Reynolds, Ph.D and Daniel R. Salomon, M.D., to its newly formed Scientific Advisory Board (SAB), expanding the SAB to four members.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, noted, “We are delighted to welcome Jack and Dan to our SAB. Our ability to recruit such key leaders in the scientific and medical industries is a testament to the strength of our technology and product pipeline. Both Jack and Dan are distinguished leaders in their respective fields. We look forward to benefiting from their guidance going forward.”

Dr. Reynolds is currently Principal of JA Reynolds & Associates and General Managing Partner of Pharma Capital Partners, a private equity fund focused on the development of early-stage pharmaceutical assets. Dr. Reynolds spent a total of almost 18 years with the Pfizer Global Research and Development division, and over 30 years in the pharmaceutical industry. Until August 2006, he was Senior Vice President of Research and Development and Worldwide Head of Safety Sciences and Comparative Medicine. During his lengthy career, Dr. Reynolds has held leadership positions of increasing responsibility at Bristol-Myers Squibb, Bayer and Pfizer. He was also the Founding Director of the Center for Molecular Safety Sciences, a joint collaboration between the non-profit Hamner Center for Molecular Safety Sciences, Duke University and the University of North Carolina.

Dr. Salomon is currently medical director of the Center for Organ and Cell Transplantation for Scripps Health at Scripps Green Hospital and is an associate professor in the department of molecular and experimental medicine at The Scripps Research Institute. He currently serves as Chairman of the Tissue Engineering Committee for the American Society of Gene and Cell Therapy (ASGCT). Dr. Salomon’s research interests include; the investigation of how molecular mechanisms driving immune cell activation and tissue injury are regulated at the gene transcriptional and proteomic level and mapping molecular networks that relate to clinical outcomes in cell and organ transplantation. Dr. Salomon previously held the position of chair of the U.S. Food and Drug Administration's Biological Response Modifiers Advisory Committee and has served on multiple NIH study sections and special emphasis panels for over 15 years.

About NexMed:

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed has embarked on a partnering program to pair the NexACT delivery technology with drugs and drug candidates marketed and being developed by others, including NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information, go to and

Copyright Business Wire 2010